These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 39261569)
1. Assessing the impact of COVID-19 non-pharmaceutical interventions and relaxation policies on Class B respiratory infectious diseases transmission in China. Wu N; Guan P; An S; Wang Z; Huang D; Ren Y; Wu W Sci Rep; 2024 Sep; 14(1):21197. PubMed ID: 39261569 [TBL] [Abstract][Full Text] [Related]
2. The secondary outcome of public health measures amidst the COVID-19 pandemic in the spread of other respiratory infectious diseases in Thailand. Ndeh NT; Tesfaldet YT; Budnard J; Chuaicharoen P Travel Med Infect Dis; 2022; 48():102348. PubMed ID: 35523394 [TBL] [Abstract][Full Text] [Related]
3. Epidemiological characteristics of seven notifiable respiratory infectious diseases in the mainland of China: an analysis of national surveillance data from 2017 to 2021. Deng LL; Han YJ; Li ZW; Wang DY; Chen T; Ren X; He GX Infect Dis Poverty; 2023 Nov; 12(1):99. PubMed ID: 37953290 [TBL] [Abstract][Full Text] [Related]
4. Collateral Impact of COVID-19 Prevention Measures on Re-Emergence of Scarlet Fever and Pertussis in Mainland China and Hong Kong China. He Y; Ma C; Guo X; Pan J; Xu W; Liu S Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011545 [TBL] [Abstract][Full Text] [Related]
5. Epidemiological trend in scarlet fever incidence in China during the COVID-19 pandemic: A time series analysis. Ma Y; Gao S; Kang Z; Shan L; Jiao M; Li Y; Liang L; Hao Y; Zhao B; Ning N; Gao L; Cui Y; Sun H; Wu Q; Liu H Front Public Health; 2022; 10():923318. PubMed ID: 36589977 [TBL] [Abstract][Full Text] [Related]
6. Impact of non-pharmaceutical interventions during COVID-19 pandemic on pertussis, scarlet fever and hand-foot-mouth disease in China. Geng Y; Zhang L J Infect; 2022 Feb; 84(2):e13-e15. PubMed ID: 34953908 [No Abstract] [Full Text] [Related]
7. Epidemiological Characteristics of Notifiable Respiratory Infectious Diseases in Mainland China from 2010 to 2018. Deng L; Han Y; Wang J; Liu H; Li G; Wang D; He G Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36900957 [TBL] [Abstract][Full Text] [Related]
8. Trends in respiratory diseases before and after the COVID-19 pandemic in China from 2010 to 2021. Zuo Z; Yang C; Ye F; Wang M; Wu J; Tao C; Xun Y; Li Z; Liu S; Huang J; Xu A BMC Public Health; 2023 Feb; 23(1):217. PubMed ID: 36721137 [TBL] [Abstract][Full Text] [Related]
9. Epidemiological changes of scarlet fever before, during and after the COVID-19 pandemic in Chongqing, China: a 19-year surveillance and prediction study. Wu R; Xiong Y; Wang J; Li B; Yang L; Zhao H; Yang J; Yin T; Sun J; Qi L; Long J; Li Q; Zhong X; Tang W; Chen Y; Su K BMC Public Health; 2024 Sep; 24(1):2674. PubMed ID: 39350134 [TBL] [Abstract][Full Text] [Related]
10. Impact of national COVID-19 restrictions on incidence of notifiable communicable diseases in England: an interrupted time series analysis. Nash K; Lai J; Sandhu K; Chandan JS; Shantikumar S; Ogunlayi F; Coleman PC BMC Public Health; 2022 Dec; 22(1):2318. PubMed ID: 36510205 [TBL] [Abstract][Full Text] [Related]
11. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Feng L; Zhang T; Wang Q; Xie Y; Peng Z; Zheng J; Qin Y; Zhang M; Lai S; Wang D; Feng Z; Li Z; Gao GF Nat Commun; 2021 May; 12(1):3249. PubMed ID: 34059675 [TBL] [Abstract][Full Text] [Related]
12. Optimal adaptive nonpharmaceutical interventions to mitigate the outbreak of respiratory infections following the COVID-19 pandemic: a deep reinforcement learning study in Hong Kong, China. Yao Y; Zhou H; Cao Z; Zeng DD; Zhang Q J Am Med Inform Assoc; 2023 Aug; 30(9):1543-1551. PubMed ID: 37364025 [TBL] [Abstract][Full Text] [Related]
13. Transmission of respiratory tract infections at mass gathering events. Petersen E; Memish ZA; Zumla A; Maani AA Curr Opin Pulm Med; 2020 May; 26(3):197-202. PubMed ID: 32149751 [TBL] [Abstract][Full Text] [Related]
14. Incidence of pulmonary tuberculosis under the regular COVID-19 epidemic prevention and control in China. Wu Z; Chen Z; Long S; Wu A; Wang H BMC Infect Dis; 2022 Jul; 22(1):641. PubMed ID: 35871653 [TBL] [Abstract][Full Text] [Related]
15. Analysis of the effectiveness of non-pharmaceutical interventions on influenza during the Coronavirus disease 2019 pandemic by time-series forecasting. Kim HK; Min KD; Cho SI BMC Infect Dis; 2023 Oct; 23(1):717. PubMed ID: 37875817 [TBL] [Abstract][Full Text] [Related]
16. Immediate and long-term changes in infectious diseases in China at the "First-level-response", "Normalized-control" and "Dynamic-COVID-zero" stages from 2020 to 2022: a multistage interrupted-time-series-analysis. Shi T; Zhang X; Meng L; Li D; Jin N; Zhao X; Zheng H; Wang T; Li R; Ren X BMC Public Health; 2023 Jul; 23(1):1381. PubMed ID: 37464368 [TBL] [Abstract][Full Text] [Related]
17. Effects of COVID-19 lockdown on epidemic diseases of childhood. Belingheri M; Paladino ME; Piacenti S; Riva MA J Med Virol; 2021 Jan; 93(1):153-154. PubMed ID: 32617991 [No Abstract] [Full Text] [Related]
18. Notifiable Respiratory Infectious Diseases in China: A Spatial-Temporal Epidemiology Analysis. Mao Y; He R; Zhu B; Liu J; Zhang N Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32235375 [TBL] [Abstract][Full Text] [Related]
19. Non-pharmaceutical interventions for COVID-19 reduced the incidence of infectious diseases: a controlled interrupted time-series study. Zhang W; Wu Y; Wen B; Zhang Y; Wang Y; Yin W; Sun S; Wei X; Sun H; Zhang Z; Li S; Guo Y Infect Dis Poverty; 2023 Mar; 12(1):15. PubMed ID: 36895021 [TBL] [Abstract][Full Text] [Related]
20. Epidemiological characteristics of common respiratory infectious diseases in children before and during the COVID-19 epidemic. Wang B; Gai X; Han Y; Liu Y; Zhang Y; Sun J; Liu M; Yu H; Peng Z; Wei X; Chang Y; Ma X; Gai Z Front Pediatr; 2023; 11():1212658. PubMed ID: 37601133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]